文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

子宫内膜癌外照射放疗中骨髓亚区剂量与急性血液学毒性的相关性

Correlation between radiation dose to bone marrow subregions and acute hematologic toxicity inendometrial cancer treated with external beam radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-02-28

腰骶椎骨髓V20 Gy<64%与<60岁患者≤20%的≥2级血液学毒性风险相关(敏感度83.3%,特异度61.5%);>70岁患者该风险独立于V20 Gy腰骶椎骨髓(95%CI 0.60-0.87;p=0.03)。

要点

  • 腰骶椎骨髓V20 Gy<64%与<60岁患者≥2级血液学毒性风险≤20%相关。
  • >70岁患者≥2级血液学毒性风险低于20%,独立于腰骶椎骨髓V20 Gy百分比。
  • 髂骨和 lower pelvis 骨髓的V10-40及Dmean与血液学毒性无关联。

核心结论

  • 本研究中提出了一种年龄依赖的剂量约束,以降低血液学毒性风险。
  • 腰骶椎骨髓接受低剂量辐射的V20 LSBM>64%似乎与年轻患者的血液学毒性相关;>70岁患者V20 Gy LSBM百分比似乎与毒性风险不相关。

研究设计与样本

  • 所有患者接受VMAT辅助外照射加阴道残端近距离放疗;有指征时术后行铂类辅助化疗( upfront或sandwich模式)。
  • 盆腔骨髓勾画并分为三个亚区:腰骶椎骨髓(LSBM)、髂骨骨髓(IBM)和 lower pelvis 骨髓(LPBM)。
  • 收集每个区域接受10、20、30和40 Gy的体积(V10、V20、V30、V40)及平均剂量(Dmean)。
  • 放疗期间血液学毒性按CTCAE V5.0分级;采用线性逻辑回归模型检验剂量学参数与HT的关联。

主要发现

  • 99例患者数据回顾性分析;辅助外照射盆腔VMAT总剂量45 Gy,1.8 Gy/次,加阴道残端近距离放疗总剂量10 Gy分2次每周。
  • 以83.3%的敏感度和61.5%的特异度,V20 Gy LSBM<64%与<60岁患者≥2级血液学毒性风险≤20%相关。
  • >70岁患者≥2级血液学毒性风险低于20%,独立于V20 Gy LSBM百分比(95%CI 0.60-0.87;p=0.03)。
  • 未观察到血液学毒性与IBM和LPBM的V10-20-30-40或Dmean之间的关联。

关键数值与推荐

  • V20 Gy LSBM<64%:与<60岁患者≥2级血液学毒性风险≤20%相关(敏感度83.3%,特异度61.5%)。
  • >70岁患者:≥2级血液学毒性风险<20%,独立于V20 Gy LSBM百分比(95%CI 0.60-0.87;p=0.03)。
  • IBM和LPBM的V10-20-30-40及Dmean与血液学毒性无关联。

临床怎么用

  • 本研究中提出年龄依赖的剂量约束以降低血液学毒性风险。
  • 未来研究应通过将上述参数纳入计划设计过程来确认这些发现。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To identify dosimetric parameters associated with acute hematologic toxicity (HT) in endometrial cancer treated with volumetric modulated arc therapy (VMAT-RT). METHODS: Patients with uterine adenocarcinoma treated in our Institution from March 2019 to November 2022 were retrospectively enrolled in this study. All patients underwent adjuvant external beam radiotherapy with Volumetric modulated arc therapy (VMAT) strategy plus a brachytherapy boost on vaginal cuff. When indicated, adjuvant platin-based chemotherapy was administered after surgery in upfront or sandwich setting. Pelvic bone marrow was contoured for each patient and divided into three subsites: lumbosacral spine (LSBM), ilium (IBM) and lower pelvis (LPBM). The volume of each region receiving 10,20,30 and 40 Gy (V10, V20, V30, V40, respectively) and mean dose (Dmean) was collected. Hematological toxicity during radiotherapy treatment was graded according to the CTCAE V 5.0. Linear logistic regression models were used to test associations between dosimetric parameters and HT. RESULTS: Data from 99 patients were retrospectively analyzed. Adjuvant external beam radiotherapy was delivered to the pelvis with Volumetric modulated arc therapy (VAMT) strategy for a total dose of 45 Gy, 1.8 Gy/fraction plus a brachytherapy boost on vaginal cuff for a total dose of 10 Gy in 2 fractions weekly. Thirty-one patients developed during radiotherapy treatment an HT ≥ grade 2.With a sensitivity of 83.3 % and specificity of 61.5 %, V20 Gy LSBM < 64 % is associated to a maximum 20 % risk of Grade 2 or worse HT in patients with < 60 years old; for patients older than 70, the risk of toxicity is below 20 % independently by the percentage volume of V20Gy LSBM (95 % CI 0.60-0.87; p = 0.03).No association between hematological toxicity and V10-20-30-40 or Dmean of IBM and LPBM were observed.Dosimetric parameters involving the lower pelvis had stronger association with hematological toxicity than those involving the ilium, even if not significant. CONCLUSIONS: In this experience a dose constraint age-dependent was proposed, to reduce the risk of HT.The volume of lombo-sacral pelvis receiving low-dose radiation (V20 LSBM > 64 %) seems to be associated with HT in younger patients; instead in older than 70 patients the percentage of V20Gy LSBM seems not correlate with risk of toxicity. Future investigations should seek to confirm these findings through the inclusion of these parameters in the planning process.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Autorino R, Cusumano D, Rinaldi RM, et al. Correlation between radiation dose to bone marrow subregions and acute hematologic toxicity inendometrial cancer treated with external beam radiotherapy. Clin Transl Radiat Oncol. 2025. PMID: 40124647. doi:10.1016/j.ctro.2025.100942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。